China Pharmaceutical (HK) Corporation Limited

Yes. China Pharmaceutical (HK) Corporation Limited is a legitimate Hong Kong corporation (Public company limited by shares) duly incorporated under the Companies Ordinance (Cap. 622) on 2005-10-06 (operating for 21 years). According to official registers of the Hong Kong Companies Registry (CR), the entity holds an active statutory standing of [Live / In Operation], possessing independent legal personality and full corporate capacity (Statutory verification: September 2026).

The statutory primary identifiers for China Pharmaceutical (HK) Corporation Limited are: 1. Business Registration Number (BRN / Unique Business Identifier UBI): [36081563] (effective from 27 December 2023, this 8-digit number issued under Cap. 310 serves as the unified cross-departmental corporate identifier); 2. Company Registration Number (CRN): [0999710] (incorporation archive number issued under Cap. 622). Together, these dual keys uniquely lock the entity in international banking KYC and cross-border contracts.

Under the Companies Ordinance (Cap. 622) of Hong Kong, incorporated companies do not maintain a single 'legal representative' position; the Board of Directors (Section 643) exercises statutory management authority. Under the New Inspection Regime, public inspection displays directors' correspondence addresses and partially masked identification numbers. Complete current and historical directorships (Form ND2A), registered member shareholdings (Form NAR1 / Section 627), and Ultimate Beneficial Ownership (UBO / SCR under Part 12 Division 2A) are verified through official statutory filing retrieval.

Yes. According to the official statutory records of the Hong Kong Companies Registry, China Pharmaceutical (HK) Corporation Limited has officially recorded 2 legal name change(s): [TONG REN TANG (HONG KONG) HOLDING LIMITED (同仁堂(香港)股份有限公司) (effective 2005-10-06)], [Company Registration Number 0999710 Limited (公司註冊編號 0999710 有限公司) (effective 2017-01-12)]. Pursuant to Sections 107 and 109 of the Companies Ordinance (Cap. 622), each name change was passed by special resolution (Form NNC2) and took statutory effect upon issuance of a Certificate of Change of Name by the Registrar of Companies; under Section 109(4), changing the company name does not affect any rights, obligations, or legal proceedings of the company.

Yes. Statutory indexing confirms that China Pharmaceutical (HK) Corporation Limited has accumulated 10 official filing dossier(s) archived in the Hong Kong Companies Registry (latest statutory filing indexed on 2025-10-09: Form NAR1 - Annual Return (2025) (English)). Pursuant to Section 662 of the Companies Ordinance (Cap. 622), private companies must deliver an Annual Return (Form NAR1) within 42 days after each incorporation anniversary. Available barcoded dossiers include: latest Annual Return (Form NAR1 - detailing current share capital, registered office, directors, and member shareholdings), Incorporation Form (Form NNC1), Articles of Association, and Change of Company Secretary and Director notices (Form ND2A), each bearing authentic ICRIS electronic barcode verification.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Officially licensed by Hong Kong statutory authorities, currently holding: Chinese Medicine Regulatory Office (CMRO) (Licence No. PM-2005-00016); 2. Judicial Screening (Litigation & Winding-Up): cross-referenced with the Hong Kong Judiciary public writs database and Official Receiver's Office (ORO) registers; no public civil action writs (HCA/DCCJ) or compulsory winding-up petitions (HCCW under Cap. 32) were found on current index records.

The statutory registered office of China Pharmaceutical (HK) Corporation Limited on official record is situated at: [ROOM J, 17/F, CENTURY CENTRE, 33-35 AU PUI WAN STREET, SHA TIN, HONG KONG]. Pursuant to Section 658 of the Companies Ordinance (Cap. 622), every Hong Kong company must maintain a registered office in Hong Kong to which all communications and legal notices may be addressed, and file Form NR1 within 15 days of any address change. Under Section 3 of the Companies (Disclosure of Company Name and Liability Status) Regulation (Cap. 622B), the company must continuously display its registered name in legible characters at its registered office.

Under Section 127 of the Companies Ordinance (Cap. 622), Hong Kong has abolished the mandatory use of a metallic common seal; China Pharmaceutical (HK) Corporation Limited (CRN: 0999710 / 8-digit BRN: 36081563) may lawfully execute a commercial contract without a common seal by having the document signed on its behalf by its sole director (for a single-director company) or by two directors / one director and the company secretary. Because commercial rubber chops are not filed with the Hong Kong Government, counterparties must retrieve the latest Annual Return (Form NAR1) and director change notices (Form ND2A) from the Companies Registry to verify that the natural person signing is an active registered director.